What it is
NA-Semax-Amidate is a modified version of Semax. Semax is a short, man-made chain of amino acids (a peptide) built from a small piece of a natural body hormone called ACTH — short for adrenocorticotropic hormone.
The name describes the two changes made to it. N-Acetyl means an acetyl group has been attached to one end of the chain. Amidate means the other end has been capped with an amide group. Both changes are standard chemistry for making a peptide harder for the body's enzymes to chop up.
It comes ready to use in an atomizer — a small pump bottle that sprays a measured mist into the nose. The bottle holds 10 milligrams of peptide in 10 millilitres of liquid, and each press of the pump delivers 100 micrograms (mcg). That is 100 sprays per bottle. There is no powder to mix and no syringe.
An important honesty note: the only information available for this compound covers handling, storage, and dosing. What it does, its benefits, its side effects, and who should avoid it have not been documented. Everything on this page that is not dosing draws on the Semax entries on this site and is marked as such.
NA-Semax-Amidate is N-acetylated, C-terminally amidated Semax. Semax itself is a synthetic heptapeptide analogue of ACTH (4-10) with a Pro-Gly-Pro extension.
The two terminal modifications — N-terminal acetylation and C-terminal amidation — are conventional peptide-stability chemistry: they remove the charged free termini that exopeptidases recognise, which generally increases metabolic stability and lipophilicity relative to the unmodified parent. That is generic peptide chemistry, not a documented property of this analogue.
Presentation: 10 mg in a 10 mL atomizer, 1 mg/mL, 100 mcg per actuation, 100 actuations per bottle. No reconstitution step; titration is stepwise in 100 mcg increments.
Data scope, stated plainly: documented information covers cycle length, dosing time, onset, storage, administration technique, dispense rate, and a two-line dose schedule. There is no published pharmacology, indication list, adverse effect list, or contraindication list for this form. The pharmacology described elsewhere on this page draws on the Semax entries on this site, marked at each point, and should be read as background on the parent molecule rather than as data on this analogue.
What it does
This has not been documented for this form; only dosing instructions are available.
What is known about the experience of using it: it starts working in 20 to 40 minutes, it is dosed from the morning to early afternoon, and you do not need an empty stomach because the spray never goes through the digestive system.
From the Semax entry on this site, for the parent compound: Semax is studied for memory and clearer thinking, for protecting nerve cells after a stroke or a head injury, and for lowering anxiety and lifting low mood in animal studies. Whether the acetyl and amide changes alter any of that is not known.
No mechanism data exist for this form; only dosing data are available.
What is specified is kinetic: 20–40 minute onset, morning to early afternoon administration window, no fasted-state requirement because the intranasal route bypasses the gastrointestinal tract, and refrigerated storage of the atomizer after use.
From the Semax entries on this site, as parent-compound background: BDNF and NGF upregulation with downstream synaptogenesis and neuroplasticity, modulation of dopaminergic, serotonergic, and noradrenergic transmission, inhibition of enkephalin-degrading enzymes, and neuroprotection against ischaemic, traumatic, and neurodegenerative insult.
How terminal acetylation and amidation shift potency, duration, or receptor engagement relative to Semax has not been characterised and is not asserted here. The longer stated onset window (20–40 minutes versus 15–30 for the Semax spray) is the only documented quantitative difference.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits have been documented for this form; only dosing data exist, and that absence is not evidence either way.Anecdotal
- What is known: onset in 20 to 40 minutes.Anecdotal
- What is known: no injection, no powder to mix, and no syringe — the atomizer sprays a fixed 100 mcg.Anecdotal
- What is known: it does not have to be taken on an empty stomach, because the spray bypasses the digestive system.Anecdotal
- From the Semax entry on this site, for the parent compound: better memory and thinking, protection of nerve cells against damage from stroke or injury, lower anxiety and improved mood in animal studies, and support for nerve cell survival and new connections between nerve cells.Animal or lab only
- Not yet established: whether any of those parent-compound benefits transfer to the acetylated, amidated form.Anecdotal
- No benefit list has been documented for this form; the absence reflects limited data, not a negative finding.Anecdotal
- Documented practical properties: 20–40 minute onset; 100 mcg per actuation with no reconstitution; intranasal delivery bypassing the gastrointestinal tract and first-pass metabolism.Anecdotal
- From the Semax entries on this site, as parent-compound background: memory enhancement, neuroprotection against ischaemic, traumatic, and neurodegenerative injury, anxiolytic and antidepressant activity in animal models, BDNF/NGF-mediated synaptogenesis and neuroplasticity, and enkephalinase inhibition.Animal or lab only
- Not yet established: whether terminal modification preserves, increases, or reduces any of the above.Anecdotal
Reconstitution and dosing
There is nothing to mix. The bottle already holds the liquid: 10 milligrams of peptide in 10 millilitres, and every press of the pump delivers 100 micrograms (mcg). That gives 100 sprays in a bottle.
Split each dose between both nostrils as far as you can. Three sprays means two in one nostril and one in the other, not three in the same one. Splitting spreads the liquid over more of the nose lining, less of it runs down the throat and gets swallowed, and absorption is steadier — at any moment one nostril is usually more blocked than the other, and using both evens that out.
Technique matters a great deal. Do not tilt your head back. Tip your head forward, angle the atomizer towards the outside of your nose — roughly towards the outer corner of your eye on that side — then sniff gently as you spray.
Dose in the morning to early afternoon. Onset is 20 to 40 minutes. You do not need an empty stomach, because the spray never reaches the digestive system. Keep the atomizer in the fridge after use.
A cycle runs 30 days, followed by 30 days off.
One reading point: the dose shown is what you take each time you dose, not a daily total to be divided up. Three sprays three times a day is 900 mcg across the day.
No reconstitution. Presentation is 10 mg in a 10 mL atomizer, 1 mg/mL, dispensing 100 mcg per actuation — 100 actuations per bottle. Titration is therefore stepwise in 100 mcg increments.
Split every dose between both nostrils. This increases exposed mucosal surface area, reduces runoff into the pharynx and loss to swallowing, and compensates for the nasal cycle, where congestion and mucus make one nostril less absorptive than the other at any given time.
Technique, as specified: head tipped forward, never back; atomizer angled laterally towards the outer canthus on the same side; gentle sniff on actuation. Head-back positioning directs solution to the pharynx rather than the olfactory and respiratory mucosa.
Timing: morning to early afternoon. Onset 20–40 minutes. Fasted state unnecessary — the intranasal route bypasses the gastrointestinal tract. Storage: refrigerate the atomizer after use.
Cycle: 30 days on, 30 days off.
Schedule reading: doses are per administration, not daily totals. The week 2–4 schedule of 300 mcg three times daily is 900 mcg per day.
The schedule terminates at week 4 while the stated cycle runs 30 days; there is no separate instruction for the last two days, and holding at the week 2–4 dose is the plain reading rather than an explicit instruction.
10 mg in 10 mL atomizer — 100 mcg per spray
Cycle: 30 days on, followed by a 30-day washout · Frequency: 2–3 doses per day, morning to early afternoon
| When | Dose | How often |
|---|---|---|
| Week 1 | 3 sprays (300 mcg) per dose | 2×/day |
| Weeks 2–4 | 3 sprays (300 mcg) per dose | 3×/day |
Who should avoid it
- No contraindications have been documented for this form. Treat that as missing information, not as clearance for everyone.
- From the Semax entry on this site: anyone pregnant or breastfeeding, anyone under 18, anyone whose hormone system is unstable, and anyone who has reacted badly to Semax — a rash, swelling, or itching after a dose is a sign of an allergic reaction, and you should stop.
- From the Semax entry on this site: anyone with a serious mental health condition, especially active psychosis (losing touch with reality), a manic episode (a period of extreme, driven high mood), or anxiety that is not under control. Caution also applies with a history of anxiety disorder, panic disorder, bipolar disorder, or schizophrenia.
- No medicine interactions have been documented for this form. That means none have been ruled out either. Go through your full medication list with a doctor before starting, particularly anything acting on the brain.
- Nasal sprays are absorbed through the lining of the nose, so an existing nasal condition — heavy congestion, recent nasal surgery, frequent nosebleeds — is worth raising with a doctor first.
- No contraindication list has been documented. Read that as absent documentation rather than an established safety profile.
- From the Semax entries on this site: pregnancy and lactation contraindicated; under 18 not established; known hypersensitivity a reason to discontinue; endocrine instability an exclusion; severe psychiatric disorder — active psychosis, mania, uncontrolled anxiety — a stated exclusion, with caution for anxiety disorder, panic disorder, bipolar disorder including hypomania, and psychotic disorders or schizophrenia.
- No drug interactions have been documented. Nothing has been excluded, and concomitant centrally acting medication warrants review.
- Intranasal absorption depends on mucosal integrity, so nasal pathology, recent sinonasal surgery, or epistaxis history are route-specific considerations that have not been formally addressed.
- Injection-site exclusions from the subcutaneous Semax entry do not apply to this route.
Side effects
- None have been documented for this form. That is an absence of information, not a claim that there are none.
- From the Semax entry on this site: headache, nausea, trouble sleeping, anxiety, mild dizziness or light-headedness, and very rarely a small rise in blood sugar. Agitation, irritability, or restlessness are also possible.
- The one hint is indirect: dosing is restricted to the morning and early afternoon. Compounds are usually restricted that way because they can interfere with sleep.
- Any spray into the nose can irritate the lining — stinging, dryness, a runny nose, or a taste at the back of the throat are common with nasal sprays generally.
- Stop if any mental health symptom appears or gets worse.
- No adverse effect list has been documented for this form. Absent documentation, not a negative finding.
- From the Semax entries on this site: headache, nausea, insomnia, anxiety, mild dizziness or light-headedness, very rare slight increase in blood glucose, and neuropsychiatric agitation, irritability, or restlessness.
- Indirect signal: dosing is confined to morning through early afternoon, which is the usual handling for a compound with an insomnia liability.
- Local intranasal tolerance effects — mucosal irritation, stinging, rhinorrhoea, posterior nasal drip and associated taste — are generic to the route and have not been specifically documented for this form.
- Injection site reactions listed for subcutaneous Semax do not apply to this route.
- Discontinue if clinically significant psychiatric symptoms emerge or worsen.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The unmodified parent compound in the same spray format. Its entry supplies the background, benefits, and safety information above. Running both at once means taking two versions of the same peptide, so count the total.
The parent molecule, same route, same 100 mcg per actuation. It carries the pharmacology and safety documentation referenced on this page. Concurrent use is duplicative rather than complementary — total daily exposure should be counted across both.
The usual partner for Semax-family peptides. Selank is calming where the Semax family is activating, and it comes in the same kind of spray bottle so the routine matches.
The canonical Semax-family pairing: tuftsin-derived GABAergic anxiolysis against monoaminergic activation, both contributing BDNF-mediated plasticity. Route-matched as an atomizer, so dosing schedules align. No stacks have been documented specifically for this compound; this is a cross-reference from the Semax entries on this site.
Dosing figures have been reviewed and units are recomputed from the stated protocol.